JPMorgan raised the firm’s price target on Amicus (FOLD) to $18 from $16 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect a December 2026 target versus 2025 previously.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Therapeutics Reports Strong Growth Amid Strategic Advances
- Strong Growth and Strategic Expansion Drive Buy Rating for Amicus Therapeutics
- Amicus Therapeutics: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Amicus Therapeutics Reports Strong Q2 2025 Growth
- Amicus Therapeutics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating